



Re: Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A Prospective Italian Multicentric Study

Capece M¹, Cocci A², Russo G³, Cito G², Giubilei G⁴, Cacciamani G⁵, Garaffa G⁶, Falcone M⁷, Timpano M⁷, Tasso G², Sessa F², Campi R², Di Maida F², Cai T⁸, Morelli G⁹, Giammusso B³, Verze P¹, Palmieri A¹, Ralph D⁶, Mirone V¹, Mondaini N¹⁰

¹Università degli Studi di Napoli Federico II Faculty of Medicine, Department of Neuroscience, Reproductive Sciences and Dentistry, Napoli, Italy

²Azienda Ospedaliero Universitaria Careggi Faculty of Medicine, Department of Urology, Firenze, Italy

³Università degli Studi di Catania Scuola Faculty of Medicine, Department of Urology, Catania, Italy

⁴Azienda USL Toscana Centro Sede di Empoli, Department of Urology, Empoli, Italy

⁵Azienda Ospedaliera Universitaria Integrata Verona Faculty of Medicine, Verona, Italy

⁶The Institute of Urology, London, UK

⁷Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino Faculty of Medicine, Department of Urology, Torino, Italy

⁸Santa Chiara Hospital, Clinic of Urology, Trento, Italy

⁹Università di Pisa Faculty of Medicine, Department of Urology, Pisa, Italy

¹⁰Ospedale Santa Maria Annunziata, Clinic of Urology, Bagno a Ripoli, Italy

Andrology 2018;6:564-567. doi: 10.1111/andr.12497. Epub 2018 May 7.

EDITORIAL COMMENT

Collagenase clostridium histolyticum (CCH) is the first licensed drug for the treatment of Peyronie's disease and is indicated in patients with palpable plaque and a curvature deformity of $\geq 30^\circ$. This multicentric study focused on the results of CCH injections performed in five centers in Italy. A total of 135 patients have completed the treatment with three injections of CCH (0.9 mg) given at 4-week intervals in combination with home modeling activities including stretching and vacuum device use on a daily basis. An improvement in the angle of curvature was recorded in 94.8% of the patients by a mean of 19° (0-40°) or 42.9% (0-67%) from baseline ($p < 0.001$). There was a statistically significant improvement in all international index of erectile function and physician data query questionnaires subdomains. This prospective multicentric study confirms that the three-injection protocol is effective enough to achieve a good result and to minimize the cost of the treatment.

Emre Bakırcıoğlu, MD